Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End-Use (Hospitals, Cardiac Centers, Others) and By Country(UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of MEA) Forecasts, 2024-2032

Market Overview

The Middle East and Africa cardiac resynchronization therapy market witnessed significant growth in the past and is expected to grow at a CAGR of 7.6% during the forecast period (2022-2030).

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

Highlights

• CRT-D dominates the market by Product. 
• Hospitals dominate the market by End-users.
• South Africa dominates the market by Country.

Market Dynamics

Middle east and africa cardiac resynchronization therapy (crt) market drivers

Rising awareness about cardiac resynchronization therapy (crt)

Cardiac Resynchronization Therapy is a treatment that synchronizes the contractions of the left and right ventricles of the heart using electrical impulses. Patients with heart failure who have left ventricular dysfunction and a large QRS complex on their electrocardiogram (ECG) can benefit from it. Due to the efforts of medical device companies, healthcare professionals, and governmental organizations, Cardiac Resynchronization Therapy awareness is rising in the Middle East and Africa.

Middle east and africa cardiac resynchronization therapy (crt) market restraints

Complications associated with cardiac resynchronization therapy

The most frequent problem with CRT devices is an infection, which can happen at the lead or the incision site. Serious complications from infection, like sepsis and death, are possible. Another frequent problem is lead dislodgement, which can happen if the lead is not correctly fastened. Lead displacement increases the risk of infection and can result in pacing or sensing loss. The battery in CRT devices must be changed every 5-7 years. The gadget will stop working if the battery is not changed. These complications are restraints in the Middle East and Africa Cardiac Resynchronization Therapy Market.

Middle east and africa cardiac resynchronization therapy (crt) market opportunities

Regulatory support

The effectiveness and safety of medical devices, including CRT devices, are significantly influenced by regulatory authorities. Governments in the Middle East and Africa frequently collaborate closely with regulatory bodies to create strong regulatory frameworks and speed up the licensing processes for medical devices. Regulatory support enables CRT producers to efficiently introduce their goods to the market, supporting market growth. This is done by presenting a clear path for market entry.

Regional Analysis

Segmental Analysis

The Middle East and Africa cardiac resynchronization therapy (CRT) market is segmented based on Product, End-User, and Country.

Based on OS, the Middle East and Africa market is segmented by CRT-D and CRT-P.

CRT-D dominated the market over the forecast period.

Based on End-Users, the Middle East and Africa market is segmented by Hospitals, Cardiac Centre.

Hospitals dominated the market over the forecast period.

Regional Analysis of the Cardiac Resynchronization Therapy (CRT) Market

The Middle East and Africa market is segmented by country into South Africa, Saudi Arabia, and UAE. South Africa dominates the country market and is expected to grow at a CAGR of 7.7% during the forecast period.

The MEA cardiac resynchronization therapy market is anticipated to grow due to key companies' initiatives and growing awareness of cardiovascular events in developing economies. Additionally, the presence of regional distributors and growing efforts to increase public awareness of heart health are anticipated to support market expansion in the upcoming years. According to a study done in Africa between 2011 and 2018, the region lacked widespread access to and utilization of cardiac arrhythmia services. CRT was discovered to be used in 12% or 52% of the responding African nations. Of the 23 countries that responded, 52% reported implanting CRT-P, while 45% reported implanting CRT-D. The cost was a substantial deterrent to using CRT-P and CRT-Ds in the area. The study identified key objectives for expanding cardiac arrhythmia services across Africa: increased economic investments, human resource training, and infrastructure improvements in the healthcare sector.

Recent Developments

• May 2023- Medtronic declared that their new CRT device, the Micra Transcatheter Pacing System, has received FDA approval. The Micra is the smallest and lightest CRT device available, and it may be inserted into the heart without requiring open-heart surgery.
• Apr 2023- Lepu Medical Technology Co., Ltd. announced that its new CRT device, the Lepu 1000 CRT Device, has gained the CE Mark. Biventricular pacing, rate response, and anti-tachycardia pacing are just a few of the capabilities the Lepu 1000's full-featured CRT device offers.